PSL invests in UK facility for process optimisation of microsphere drugs – Lab Innovations UK

PSL invests in UK facility for process optimisation of microsphere drugs


Powder Systems Ltd (PSL) has announced its investment in a new Centre of Process Excellence (COPE) at its UK facility in response to the growing demand from global pharmaceutical manufacturers for providing additional process optimisation of their microsphere drugs.
Microspheres or micro-particles are complex drug formulations combining an API with an FDA-approved polymer such as PLGA. Microsphere drugs enable the sustained release of APIs into patients over prolonged periods of time, varying from weeks up to several months.

Despite their benefits for millions of patients around the world, microspheres are notoriously known to be difficult to process and develop for drug manufacturers.

The new COPE facility will officially open on September 2020. The facility will be opened as part of the upcoming Microsphere Summit organised by PSL in Liverpool (9–10 September). Drug manufacturers will be attending from Europe, America and Asia.

The facility will be designed to mirror the existing services currently provided by another COPE facility that opened in Philadelphia, US, in 2015. It will focus on optimising complex drug formulation processes such as filtration, drying, yield recovery and scale-up of microspheres.

“We are seeing an increase in demand from global microsphere drug players, including big pharma and generic manufacturers, for a range of additional process services to be completed prior to delivery of our technology at their production sites,” said Amanda Gowans, CEO of Powder Systems Group.





Scroll to Top